163 related articles for article (PubMed ID: 11364429)
1. How far can you knock down HIV? An interview with David D. Ho, MD. Interview by Mark Mascolini.
Ho DD
J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):40-4. PubMed ID: 11364429
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Pouncing on the chemokine receptor Chimera.
Mascolini M
J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):13-24. PubMed ID: 11364629
[TBL] [Abstract][Full Text] [Related]
4. New antiretroviral tactics: transitions or mere trends? An interview with Joep Lange,MD,PhD. Interview by Mark Mascolini.
Mascolini M
J Int Assoc Physicians AIDS Care; 1999 Jul; 5(7):25-9. PubMed ID: 11367133
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
6. HIV research overview: interview with David Ho, M.D. Interview by John S. James.
Ho D
AIDS Treat News; 1997 Nov; (No 282):1-6. PubMed ID: 11364903
[TBL] [Abstract][Full Text] [Related]
7. Protease inhibitors: implications for HIV research and treatment.
Churchill SA
J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325
[TBL] [Abstract][Full Text] [Related]
8. Long-term strategies: should some patients wait to start protease inhibitors? Interview with Keith Henry, M.D. Interview by John S. James.
Henry K
AIDS Treat News; 1997 Oct; (No 281):1, 3-6. PubMed ID: 11364791
[TBL] [Abstract][Full Text] [Related]
9. An interview with Anthony S. Fauci, MD. Interview by Mark Mascolini.
Fauci AS
J Int Assoc Physicians AIDS Care; 1996 Sep; 2(9):18-25. PubMed ID: 11363890
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
11. [[ABC of the antivirals] Project Inform].
Sidahora; 1996; ():19-32. PubMed ID: 11364292
[TBL] [Abstract][Full Text] [Related]
12. Protease inhibitors and nucleosides: how many? when? An interview with Stefano Vella, MD. Interview by Mark Mascolini.
Vella S
J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):12-8. PubMed ID: 11363089
[TBL] [Abstract][Full Text] [Related]
13. Somewhere over the rainbow...
Gilden D
GMHC Treat Issues; 1997 Feb; 11(2):1-4. PubMed ID: 11364105
[TBL] [Abstract][Full Text] [Related]
14. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitors: resistance, resistance, resistance.
Gilden D; Falkenberg J; Torres G
GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
[TBL] [Abstract][Full Text] [Related]
19. In search of the Holy Grail: Martin Markowitz, M.D., on the dream of eradication.
Markowitz M
Res Initiat Treat Action; 1998 Apr; 4(2):9-13. PubMed ID: 11365230
[TBL] [Abstract][Full Text] [Related]
20. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
